MX2023001678A - Metodos para tratar esclerosis multiple con ocrelizumab. - Google Patents

Metodos para tratar esclerosis multiple con ocrelizumab.

Info

Publication number
MX2023001678A
MX2023001678A MX2023001678A MX2023001678A MX2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A MX 2023001678 A MX2023001678 A MX 2023001678A
Authority
MX
Mexico
Prior art keywords
ocrelizumab
multiple sclerosis
treating multiple
methods
grams
Prior art date
Application number
MX2023001678A
Other languages
English (en)
Inventor
Marianna Manfrini
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2023001678A publication Critical patent/MX2023001678A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Soy Sauces And Products Related Thereto (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos para tratar esclerosis múltiple (MS) en un paciente mediante el uso del anticuerpo anti-CD20 ocrelizumab, y a un artículo de elaboración con instrucciones para tal uso. En particular, se refiere a un régimen de dosis de ocrelizumab en donde la dosis inicial y la segunda son de 1.2 gramos para pacientes de menos de 75 kg de peso o de 1.8 gramos para pacientes de 75 kg o más en un intervalo de alrededor de 6 meses.
MX2023001678A 2020-08-14 2021-08-12 Metodos para tratar esclerosis multiple con ocrelizumab. MX2023001678A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066077P 2020-08-14 2020-08-14
US202063072673P 2020-08-31 2020-08-31
PCT/US2021/045792 WO2022036129A1 (en) 2020-08-14 2021-08-12 Methods for treating multiple sclerosis with ocrelizumab

Publications (1)

Publication Number Publication Date
MX2023001678A true MX2023001678A (es) 2023-02-22

Family

ID=77911120

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001678A MX2023001678A (es) 2020-08-14 2021-08-12 Metodos para tratar esclerosis multiple con ocrelizumab.

Country Status (10)

Country Link
US (2) US20220064320A1 (es)
EP (1) EP4196223A1 (es)
JP (1) JP2023537751A (es)
KR (1) KR20230048422A (es)
CN (1) CN116322765A (es)
AU (1) AU2021324842A1 (es)
CA (1) CA3190803A1 (es)
IL (1) IL300415A (es)
MX (1) MX2023001678A (es)
WO (1) WO2022036129A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024163542A2 (en) 2023-02-01 2024-08-08 Principia Biopharma Inc. Methods of diagnosing and treating multiple sclerosis

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU740284B2 (en) 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2433353C (en) 2000-12-28 2017-03-21 Altus Biologics, Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
BRPI0316779B1 (pt) 2002-12-16 2020-04-28 Genentech Inc anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados
EP3130349A1 (en) * 2004-06-04 2017-02-15 Genentech, Inc. Method for treating multiple sclerosis
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
TW201014605A (en) * 2008-09-16 2010-04-16 Genentech Inc Methods for treating progressive multiple sclerosis
KR20180075537A (ko) * 2015-10-06 2018-07-04 제넨테크, 인크. 다발성 경화증을 치료하기 위한 방법

Also Published As

Publication number Publication date
CN116322765A (zh) 2023-06-23
CA3190803A1 (en) 2022-02-17
JP2023537751A (ja) 2023-09-05
KR20230048422A (ko) 2023-04-11
WO2022036129A1 (en) 2022-02-17
IL300415A (en) 2023-04-01
AU2021324842A1 (en) 2023-03-02
US20220064320A1 (en) 2022-03-03
EP4196223A1 (en) 2023-06-21
US20230322942A1 (en) 2023-10-12

Similar Documents

Publication Publication Date Title
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
TW200628169A (en) Method for treating vasculitis
MX2023001678A (es) Metodos para tratar esclerosis multiple con ocrelizumab.
Mostolizadeh et al. Mathematical model of chimeric anti-gene receptor (CAR) T cell therapy with presence of cytokine
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2023012465A (es) Regimen de dosificacion de anti-ifnar1 para inyeccion subcutanea.
MX2021013910A (es) Metodos para administrar un anticuerpo anti-cd38 para tratar el mieloma multiple.
MX2022013923A (es) Metodos para tratar la enfermedad de crohn con el anticuerpo especifico anti-il23.
MX2020001254A (es) Combinacion terapeutica de un inhibidor tirosina quinasa del egfr de tercera generacion y un inhibidor raf.
BRPI0716929A8 (pt) tratamento de esclerose múltipla com campath-1h
MX2022005628A (es) Regimen de dosificacion para agentes anti-bcma.
MX2022005596A (es) Regimen de dosificacion para agentes anti-dll3.
JOP20170044B1 (ar) تركيبة صيدلانية تشتمل على hgh ناتج عن عودة الارتباط الجيني لعلاج نقص هرمون النمو
MX2022003010A (es) Tratamiento de la emr mediante cambio de terapia.
WO2021226442A3 (en) Therapeutic uses of c3-binding agents
MX2022003266A (es) Dosis para anticuerpos anti-triptasa.
AU2020319677A8 (en) Dosage and administration regimen for the treatment or prevention of C5-related diseases by the use of the anti-C5 antibody Crovalimab
Lee et al. Paroxysmal autonomic instability with dystonia managed using chemodenervation including alcohol neurolysis and botulinum toxin type a injection: a case report
Franklin et al. Clinical studies with cortisone by mouth, cortisone by injection, and ACTH in the treatment of asthma
MX2023011047A (es) Dc009 para el tratamiento de accidente cerebro-vascular isquemico agudo.
Baraka et al. Benzodiazepine treatment of penile erection under general anesthesia
NZ769607A (en) Methods for treating atopic dermatitis by administering an il-4r inhibitor
NZ763815A (en) Methods of using and compositions containing dulaglutide
MX2023014898A (es) Terapia combinada anti-vhc ventajosa.